Spiriva is a brand name for the medication tiotropium bromide, which belongs to the class of long-acting anticholinergic inhalers. It is prescribed for the maintenance treatment of chronic obstructive pulmonary disease to improve lung function. The drug works by binding to muscarinic receptors in the airway smooth muscle and preventing the action of acetylcholine that would cause bronchoconstriction. This inhibition leads to relaxation of the airway muscles and easier breathing. By providing a prolonged effect lasting up to 24 hours, Spiriva helps reduce symptoms such as wheezing and shortness of breath over the long term. The therapeutic benefit results from sustained bronchodilation that decreases the frequency of copd exacerbations.

Spiriva is a once-daily inhaler that provides maintenance bronchodilation for chronic obstructive pulmonary disease. The drug contains tiotropium bromide, a long-acting anticholinergic agent. It works by blocking muscarinic receptors in the airway smooth muscle. This blockade prevents acetylcholine from causing bronchial constriction. As a result the airway tissues relax and airflow improves. The long-acting effect lasts for up to 24 hours after each dose. Continuous receptor blockade reduces chronic inflammation and improves lung function over time. By keeping the bronchi open Spiriva helps patients breathe more easily without acute rescue therapy.

The most common side effects often include mild headache or fatigue. Some individuals may experience temporary nausea without vomiting. Occasional dizziness can occur especially after initial dosing. Skin irritation at the application site is frequently reported. Mild muscle aches have been observed in a small percentage of users. These effects typically resolve without intervention within a short period. Monitoring for persistent symptoms is part of routine clinical observation.

The most common side effects of many medications include mild headache and fatigue. Some people may experience temporary nausea or dizziness after taking certain treatments. Skin irritation or redness can occur with topical applications. A small number of individuals report mild digestive discomfort such as bloating. Headaches and muscle aches are frequently reported during the first few days of therapy. Slight changes in appetite or sleep patterns may be observed in some users. These reactions are generally short lived and often resolve without intervention.